SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aventus Network

Aventus Network ($AVT) is trending as the community discusses its potential and notes its listing on Coinbase and Mexc. Excitement is building around strategic partnerships and its role in enterprise blockchain solutions. Some community members are speculating on potential price movements and future growth.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community rallies around the project, energized by its listing on Jupiter and the low cost to become a millionaire in $UPDOG. Community members are actively asking, "What's UpDog?" and highlighting the project's strong community vibes and joke-meta pioneer status on the Solana network. The $UPDOG community is also celebrating collaborations and cross-community support with $BROKE and $WAGMI.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending after securing a $75 million investment from an undisclosed institutional investor, fueling speculation about a potential partnership with a major AI player like NVIDIA. The community is buzzing with excitement over the possibilities, especially given POET's innovative optical interposer technology that addresses AI data transmission bottlenecks. With a strengthened balance sheet and key partnerships already in place, POET is viewed by many as a long-term growth story in the booming AI and data center connectivity market.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

GLD is surging to new all-time highs, breaking the $4,000 mark, as investors seek safe-haven assets amid growing economic and political uncertainty, including a U.S. government shutdown. Community discussions revolve around whether this rally is sustainable, with some citing potential pullbacks while others point to strong central bank demand and a weakening dollar as continuing tailwinds. The broader context involves gold potentially outperforming traditional assets and serving as a hedge against inflation and a declining dollar.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's stock is trending as the company introduces cheaper versions of its Model Y and Model 3, sparking debate about brand dilution and market share. Community discussions revolve around whether these moves will boost sales volume or cheapen the brand, especially with competitors offering compelling alternatives. Some traders believe this could signal a buying opportunity, while others express concerns over profit margins and Tesla's long-term strategy.

Universe Pharmaceuticals, Inc. is a pharmaceutical company. The firm is focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. It also sells biomedical drugs, medical instruments, traditional Chinese medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. The company was founded on March 2, 1998 and is headquartered in Ji'an, China.

Universe Pharmaceuticals INC

UPC is trending as traders discuss its low float, substantial cash reserves, and potential for a significant breakout. The community is speculating on possible upcoming news or a strategic move that could trigger a rally, while also drawing comparisons to other recently volatile low-float stocks. Some investors believe the company is undervalued given its assets, while others are wary due to its history.

AlphaTON Capital Corp. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. Its portfolio includes first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. The company was founded by Gregory H. Bailey and James Mellon in 1973 and is headquartered in Road Town, British Virgin Islands.

AlphaTON Capital Corp.

ATON is trending due to its potential in the crypto space, particularly surrounding its treasury strategy focused on TON tokens and partnership with Telegram, which has over one billion monthly active users. The community is discussing the company's leadership team, particularly CEO Brittany Kaiser's experience, and anticipating further developments related to its digital asset initiatives. Speculation about a potential short squeeze and comparisons to other low-float runners are also contributing to the increased attention.

Trilogy Metals, Inc. engages in the development and exploration of mineral properties. The firm holds interests in the Upper Kobuk mineral projects that include the Arctic, a copper-zinc-lead-gold-silver and Bornite, a carbonate-hosted copper projects, which is located in the Ambler mining district in Northwest Alaska. The company was founded on April 27, 2011 and is headquartered in Vancouver, Canada.

Trilogy Metals Inc

TMQ is surging due to a recent U.S. government investment and approval of the Ambler Road project, sparking excitement about the company's potential in critical minerals. The community is actively discussing a possible short squeeze and the potential for the stock to reach double digits, while also weighing the possibility of a sell-off or secondary offering. This move reflects a broader push to secure domestic mineral resources.

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Galecto Inc

Galecto Inc. is trending due to a significant surge in price and volume, reminiscent of other recent low-float runners. The community is actively discussing potential short squeezes, high borrowing rates, and the stock's limited float, contributing to its volatile price action. Some traders caution about pump-and-dump dynamics, while others anticipate further upward momentum.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending amid community discussions about positive data, a potential short squeeze, and speculation around a buyout. Investor confidence seems to be returning, with many highlighting the stock's undervaluation and upcoming catalysts like conference presentations and earnings. Community members are closely watching resistance levels and expressing optimism about the stock's long-term potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why eFFECTOR Therapeutics (EFTR) Shares Are Down Over 70%

EFFECTOR Therapeutics shares are trading lower by 74% during Monday's session. The company announced that it has terminated its employees and will wind down its operations.
read more...

eFFECTOR Therapeutics trading resumes

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator...

eFFECTOR Therapeutics trading halted, news pending

eFFECTOR Therapeutics (NASDAQ:EFTR) Stock Rating Reaffirmed by HC Wainwright

eFFECTOR Therapeutics (NASDAQ:EFTR - Get Free Report)s stock had its "buy" rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on...

eFFECTOR Therapeutics (NASDAQ:EFTR) Earns Buy Rating from HC Wainwright

eFFECTOR Therapeutics (NASDAQ:EFTR  Get Free Report)s stock had its buy rating reissued by equities researchers at HC Wainwright in a note issued to investors on Thursday...

Buy Rating for eFFECTOR Therapeutics Backed by Solid Financials and Promising Zotatifin Trials

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on eFFECTOR Therapeutics (EFTR Research Report). The associated price ta...

eFfector Therapeutics reports Q4 EPS ($3.42), consensus ($1.65)

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024 Median progression free...

eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator...

eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of a new class oncology drugs known as selective translation regulator inhibitors (STRIs). Its STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). The company was founded by Kevan Shokat, Davide Ruggero, and Siegfried Reich on May 1, 2012 and is headquartered in Solana Beach, CA.

eFFECTOR Therapeutics Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

EFTR eFFECTOR Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest EFTR News